MedTrace Logo

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

NCT00837564 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-06-30

No results posted yet for this study

Summary

60 patients with chronic major depressive disorder according to DSM-IV will be included into the study. Patients will be randomized to receive an open treatment either with CBASP, a psychotherapy for chronic depression, or pharmacological treatment with Escitalopram for 28 weeks.

Conditions

  • Chronic Depression

Interventions

OTHER

CBASP psychotherapy

specific psychotherapy for chronic depression

DRUG

Escitalopram

Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management

Sponsors & Collaborators

  • University Hospital, Bonn

    collaborator OTHER

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Claus Normann, MD · University of Freiburg, Dep. of Psychiatry

  • Dieter Schoepf, MD · University of Bonn, Clinic for Psychiatry and Psychotherapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-04-30
Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837564 on ClinicalTrials.gov